Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to curb opioid withdrawal without drugs

NCT ID NCT04916600

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a device called NET that uses mild electrical stimulation to reduce opioid withdrawal symptoms. It involves 108 adults who want to stop using opioids without taking other medications. Participants are randomly assigned to get real or sham device treatment, and researchers measure withdrawal severity and abstinence over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NET device (a non-invasive electrical stimulation device)
What this could lead to
If it works, this could offer a drug-free way to manage opioid withdrawal symptoms, helping people achieve abstinence without medication.
What could go wrong
This is an early-stage study with only 108 participants, and it compares the device to a sham (fake) device. The device may not work better than placebo, and long-term effectiveness is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

108 people

The number who actually took part.

Started

Nov 2021

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study (including inpatient stay and participation in video assessments and remote drug screens for the duration of the 12-week outpatient study period). 3. Stated desire to be opioid abstinent without medications for treating opioid use disorder. 4. Male or female, aged 18-65 years. 5. In good general health as evidenced by medical history. 6. Meet Diagnostic and Statistical Manual (DSM)-5 criteria for opioid use disorder (any severity level) alone or comorbid with stable medical diseases (except for certain medications below). 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method for the duration of the study. 8. Initiating opioid discontinuation at Isaiah House. 9. Clinical Opiate Withdrawal Scale (COWS) total score is 13 or greater. Exclusion Criteria: 1. Acute/unstable illness: conditions making it unsafe to participate. 2. Chronic illnesses: primarily seizures and dementing illnesses, including medications for these neurological conditions. 3. Current serious psychiatric disease: psychosis, bipolar disorder. 4. Requiring detoxification from alcohol or benzodiazepines. 5. Current use of anxiolytics, hypnotics (prescription and over the counter), antidepressants, anticonvulsants, sedating histamine-1 receptor subtype antihistamines (non-sedating second generation histamine-4 receptor subtype antihistamines are allowed), prescription and over the counter stimulants. 6. Current diagnosis other than opioid use disorder requiring chronic opioid treatment. 7. Presence of a cardiac pacemaker. 8. Pregnancy or lactation. Females who do not agree to sexual abstinence or are heterosexually active and not using (self-report) medically approved birth control measures (sterilization, tubal ligation, oral/depot contraceptives, abstinence, intrauterine device, barrier method such as condom/foam, or a cervical cap combined with a spermicide), are not eligible. 9. Receiving extended-release buprenorphine (Sublocade) within 300 days of enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Isaiah House Treatment Center

    Willisburg, Kentucky, 40078, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.